Treating non-small-cell lung cancer with a RET kinase inhibitor, Selpercatinib
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on January 12th, 2024
|
In pregnancy, SARS-CoV-2 infection poses risks to both the mother and the fetus. As a result, prioritizing vaccination for this group has been crucial. While earlier observational studies demonstrated vaccine safety for the fetus, they had limitations in the scope of outcomes examined. A recent article in the Journal of the American Medical Association aims to delve deeper into understanding the impact of COVID-19 mRNA vaccines on neonatal health.
The retrospective cohort study utilized health data gathered from Ontario, Canada, spanning from May 2021 to September 2022. Examining 142,006 infants, the average gestational age at birth was approximately 38.7 weeks. Among these infants, around 60% were exposed to at least one dose of the COVID-19 mRNA vaccine while in the womb. Following a 28-day monitoring period, researchers found that neonates born to mothers vaccinated during pregnancy had a 53% reduced risk of mortality. Moreover, infants exposed to the COVID-19 mRNA vaccine prenatally exhibited a 14% lower risk of severe morbidity and a 14% reduced likelihood of admission to the neonatal intensive care unit.
The retrospective cohort study utilized health data gathered from Ontario, Canada, spanning from May 2021 to September 2022. Examining 142,006 infants, the average gestational age at birth was approximately 38.7 weeks. Among these infants, around 60% were exposed to at least one dose of the COVID-19 mRNA vaccine while in the womb. Following a 28-day monitoring period, researchers found that neonates born to mothers vaccinated during pregnancy had a 53% reduced risk of mortality. Moreover, infants exposed to the COVID-19 mRNA vaccine prenatally exhibited a 14% lower risk of severe morbidity and a 14% reduced likelihood of admission to the neonatal intensive care unit.